From prodromal stages to clinical trials: The promise of digital speech biomarkers in Parkinson's disease

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68407700%3A21230%2F24%3A00377874" target="_blank" >RIV/68407700:21230/24:00377874 - isvavai.cz</a>

Result on the web

<a href="https://doi.org/10.1016/j.neubiorev.2024.105922" target="_blank" >https://doi.org/10.1016/j.neubiorev.2024.105922</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.neubiorev.2024.105922" target="_blank" >10.1016/j.neubiorev.2024.105922</a>

Result language

angličtina

Original language name

From prodromal stages to clinical trials: The promise of digital speech biomarkers in Parkinson's disease

Original language description

Speech impairment is a common and disabling symptom in Parkinson's disease (PD), affecting communication and quality of life. Advances in digital speech processing and artificial intelligence have revolutionized objective speech analysis. Given the complex nature of speech impairment, acoustic speech analysis offers unique biomarkers for neuroprotective treatments from the prodromal stages of PD. Digital speech biomarkers can monitor levodopa-induced motor complications, detect the effects of deep brain stimulation, and provide feedback for behavioral speech therapy. This review updates the mechanisms underlying speech impairment, the impact of speech phenotypes, and the effects of interventions on speech. We evaluate the strengths, potential weaknesses, and suitability of promising digital speech biomarkers in PD for capturing disease progression and treatment efficacy. Additionally, we explore the translational potential of PD speech biomarkers to other neuropsychiatric diseases, offering insights into motion, cognition, and emotion. Finally, we highlight knowledge gaps and suggest directions for future research to enhance the use of quantitative speech measures in disease-modifying clinical trials. The findings demonstrate that one year is sufficient to detect disease progression in early PD through speech biomarkers. Voice quality, pitch, loudness, and articulation measures appear to capture the efficacy of treatment interventions most effectively. Certain speech features, such as loudness and articulation rate, behave oppositely in different neurological diseases, offering valuable insights for differential diagnosis. In conclusion, this review highlights speech as a biomarker in tracking disease progression, especially in the prodromal stages of PD, and calls for further longitudinal studies to establish its efficacy across diverse populations.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30210 - Clinical neurology

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Neuroscience and Biobehavioral Reviews

ISSN

0149-7634

e-ISSN

1873-7528

Volume of the periodical

167

Issue of the periodical within the volume

December

Country of publishing house

GB - UNITED KINGDOM

Number of pages

16

Pages from-to

—

UT code for WoS article

001344387900001

EID of the result in the Scopus database

2-s2.0-85207034898